New data on risk vs benefit for potent CAR-T cancer drugs
A promising but risky new group of customized cancer drugs will be in focus this weekend at the annual meeting of the American Society of Hematology (ASH), where clinical trial results will help clarify their potential for doctors and investors.

Experimental chimeric antigen receptor T-cells, or CAR-Ts, are made by genetically altering a patients' own T-cells in the lab to help the immune system find and kill cancer cells. The altered cells are then infused back into the patient....

http://www.reuters.com/article/us-cancer-kite-pharma-idUSKBN13R2PZ
Like
Comment
Share